Silo Pharma (NASDAQ: SILO) Files Patent for Ibogaine Therapy Targeting Brain Injuries
Expert Analysis Silo Pharma (NASDAQ: SILO) is strategically advancing its position in the rapidly developing psychedelic medicine sector by filing a provisional patent for an ibogaine-based therapeutic designed to address traumatic brain injury (TBI). This move highlights the company’s commitment to innovation in neuropsychiatric treatments and signals its alignment with federal efforts to accelerate mental health solutions. The potential of ibogaine as a neurotherapeutic agent places Silo Pharma at the…









